TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA WITH NUCLEOSIDE ANALOGS

被引：17

作者：

DIMOPOULOS, MA

OBRIEN, S

KANTARJIAN, H

ESTEY, EE

KEATING, MJ

ALEXANIAN, R

机构：

[1] The University of Texas, M. D. Anderson Cancer Center, Houston, TX

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

FLUDARABINE; WALDENSTROMS MACROGLOBULINEMIA; 2-CHLORODEOXYADENOSINE; NUCLEOSIDE ANALOGS;

D O I：

10.3109/10428199309064269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sixty-eight patients with Waldenstrom's macroglobulinemia were treated either with fludarabine (28 patients) or 2-chlorodeoxyadenosine (40 patients) and responding patients were followed without further treatment. Both programs were well tolerated and myelosuppression was moderate but reversible. Overall, 35 patients responded including 93% of previously untreated patients, 83% of those relapsing off therapy, 48% of patients with primary refractory disease and 15% of those treated during refractory relapse. With a median follow up of 18 months, only two of 15 previously untreated patients have relapsed whereas the median remission duration and survival of previously treated patients were 38 and 43 months respectively. Fludarabine and 2-chlorodeoxyadenosine are both highly active agents against Waldenstrom's macroglobulinemia, especially when administered early in the disease course.

引用

页码：105 / 108

页数：4

共 21 条

[1]

MacKenzie M.R., Fudenberg H.H., Macroglobulinemia-an analysis of forty patients, Blood, 39, pp. 874-889, (1972)

[2]

Petrucci M.T., Avvisati G., Tribalto M., Giovangrossi P., Mandelli F., Waldenstrom's macroglobulin-emia—results in 34 newly diagnosed patients, J. Intern. Med., 26, pp. 443-447, (1989)

[3]

Case D.C., Ervin T.J., Boyd M.A., Redfield D.L., Waldenstrom's macroglobulinemia: Long term results with the M-2 protocol, Cancer Invest., 9, pp. 1-7, (1991)

[4]

Kantarjian H.M., Alexanian R., Koller C.A., Kurzrock R., Keating M.S., Fludarabine therapy in ma-croglobulinemic lymphoma, Blood, 75, pp. 1928-1931, (1990)

[5]

Dimopoulos M.A., Kantarjian H., Estey E., O'Brien S., Delasalle K., Keating M.J., Freireich E.J., Alexanian R., Treatment of Waldenstrom's macroglobulinemia with 2–chlorodeoxyadenosine, Ann. Intern. Med., 118, pp. 195-198, (1993)

[6]

McLaughlin P., Alexanian R., Myeloma protein kinetics following chemotherapy, Blood, 60, pp. 851-854, (1982)

[7]

Claman G.H., Corder M.P., Bums C.P., Successful doxorubicin therapy of primary macroglobulinemia resistant to alkylating agents, Am. J. Hematol., 9, pp. 221-223, (1980)

[8]

Jane S.M., Salem H.H., Treatment of resistant Waldenstrom's macroglobulinemia with high dose glucoco-steroids, Aust. N.Z. J. Med., 18, pp. 77-78, (1988)

[9]

Ohno R., Kodera Y., Ogura M., Murase T., Emi N., Okumura M., Kobayashi M., Takeyama H., Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon, Cancer Chemother. Pharmacol., 14, pp. 34-37, (1985)

[10]

Quesada J.R., Alexanian R., Kurzrock R., Barlogie B., Saks S., Gutterman J.U., Recombinant interferon gamma in hairy cell leukemia, multiple myeloma and Waldenstrom's macroglobulinemia, Am. J. Hematol., 29, pp. 1-4, (1988)

← 1 2 3 →